Toggle menu

PREFER

Start date:
Historic
End date:
June 2014
Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich

Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism

 

Aim

To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE

Trial Design

Multi –national, multi-centre, prospective observational disease registry

Chief Investigator

Dr Petra Laeis, Munich

Local PI

Dr. Matt Reed

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)